Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

2(50.0%)

Early Phase 1

1(25.0%)

Phase 1

1(25.0%)

4Total

Phase 2(2)

Early Phase 1(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07471230Phase 2Not Yet Recruiting

Evaluation of Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism

Role: lead

NCT07467733Phase 1Not Yet Recruiting

Evaluation of the Safety and Preliminary Efficacy of Neuroinduced Mesenchymal Stem Cells and Exosome Therapy in Patients With Spinocerebellar Palsy

Role: lead

NCT07465198Phase 2Not Yet Recruiting

Autologous Stem Cell Therapy in Patients With Multiple System Atrophy

Role: lead

NCT07145502Active Not Recruiting

Monitoring of Outcomes of Cellular and Exosome-based Therapies in Autoinflammatory and Post-infectious Neuroinflammatory Syndromes

Role: lead

NCT07143656Active Not Recruiting

Amyotrophic Lateral Sclerosis: A Multicenter Retrospective Observational Registry

Role: lead

NCT07146087Early Phase 1Suspended

Allogeneic Mesenchymal Stem Cell-Derived Exosome Therapy for Progressive Multiple Sclerosis

Role: lead

All 6 trials loaded